Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist
AssigneeGilead Sciences, Inc.
InventorsRomas Geleziunas, Devi Sengupta, Christian Brander, Beatriz Mothe Pujadas, Ian McGowan
Life of this patent
Estimating the term…
Abstract
The present disclosure describes methods, compositions, and kits related to the combination of a TLR7 modulating compound and an HIV vaccine. The combination can be used in a method of treating or preventing an HIV infection in a human.
Claims25
A method of treating an HIV-1 infection in a human in need thereof suffering from HIV-1 infection, the method comprising administering to the human 6 mg of a compound of Formula (I):
- and a first virus that is a replication-defective chimpanzee adenovirus comprising a nucleic acid encoding an immunogenic polypeptide comprising:
- (i) a sequence having at least 90% sequence identity to SEQ ID NO:
- 1;
- (ii) a sequence having at least 90% sequence identity to SEQ ID NO:
- 2;
- (iii) a sequence having at least 90% sequence identity to SEQ ID NO:
- 3;
- (iv) a sequence having at least 90% sequence identity to SEQ ID NO:
- 4;
- (v) a sequence having at least 90% sequence identity to SEQ ID NO:
- 5;
- (vi) a sequence having at least 90% sequence identity to SEQ ID NO:
- 6;
- (vii) a sequence having at least 90% sequence identity to SEQ ID NO:
- 7;
- (viii) a sequence having at least 90% sequence identity to SEQ ID NO:
- 8;
- (ix) a sequence having at least 90% sequence identity to SEQ ID NO:
- 9;
- (x) a sequence having at least 90% sequence identity to SEQ ID NO:
- 10;
- a sequence having at least 90% sequence identity to SEQ ID NO:
- 11;
- (xii) a sequence having at least 90% sequence identity to SEQ ID NO:
- 12;
- (xiii) a sequence having at least 90% sequence identity to SEQ ID NO:
- 13;
- (xiv) a sequence having at least 90% sequence identity to SEQ ID NO:
- 14;
- (xv) a sequence having at least 90% sequence identity to SEQ ID NO:
- 15;
- and
- (xvi) a sequence having at least 90% sequence identity to SEQ ID NO:
- 16;
- wherein at least two of (i) to (xvi) are joined by a single, dual, or triple alanine amino acid linker, wherein the linker results in the formation of an AAA sequence in the junction region between adjoining sequences, and
- wherein the sequence of each of (i) to (xvi) is 11-85 amino acids in length.
A method of treating an HIV-1 infection in a virologically suppressed human in need thereof suffering from HIV-1 infection, the method comprising administering to the human a compound of Formula (I):
- a first virus comprising 5×1010 viral particles of a replication-defective chimpanzee adenovirus comprising a nucleic acid encoding an immunogenic polypeptide having an amino acid sequence of SEQ ID NO:
- 17, and
- a second virus comprising 2×108 plaque-forming units of a modified vaccinia virus Ankara (MVA) comprising a nucleic acid encoding an immunogenic polypeptide having an amino acid sequence of SEQ ID NO:
- 17;
- wherein
- the first virus is administered at Week 0 and Week 12,
- the second virus is administered at Week 24 and Week 36,
- 6 mg of the compound of Formula (I) is administered at Week 26 and Week 28, and
- 6 mg of the compound of Formula (I) is administered at Weeks 30, 32, 34, 38, 40, 42, 44, and 46.
Dependencies are inferred from the claim text.